Phase 2
Completed N=10
Dopamine Receptor Agonist Therapy for Pain Relief in Women Suffering From Endometriosis: A Pilot Study
Source: ClinicalTrials.gov NCT02542410 ↗Enrolled (actual)
10
Serious AEs
0.0%
Results posted
Feb 2020
Primary outcomePrimary: Change in Score in Worst Pain Over the Last Month — -0.5; -5 score on a scale
Summary
The proposed pilot study will estimate the efficacy and safety of a novel therapeutic agent, cabergoline, with a clinical standard therapy, norethindrone acetate, for the treatment of endometriosis-associated pain in young women with endometriosis.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Change in Score in Worst Pain Over the Last Month |
-0.5; -5 | — |
| SECONDARY Changes in Pain Interference Scores |
0.85; 0 | — |
Eligibility Criteria
Inclusion Criteria
- Surgically confirmed endometriosis
- Age between 15-40 y, and premenopausal
- Pelvic pain score ≥3 on a Visual Analog Scaleover the last month
Exclusion Criteria
- Use of other concurrent hormone medications (such as birth control pills)
- Impaired liver function (ALT > 2x normal) or liver disease (cirrhosis, hepatitis)
- Pregnancy
- Breast cancer
- Active thromboembolic disease
- Uncontrolled hypertension, history of cardiac valve disorder, history of fibrotic disorders
Data sourced from ClinicalTrials.gov (NCT02542410). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.